Furthermore, PBI-05204 which contains OLN as its active ingredient and exhibited a safe profile in Phase 1/2 clinical trials in cancer patients, suppressed the growth of patient-derived glioblastoma stem cell spheroids in part through decreased GRP78 expression (98, 99). The gene discussed is HSPA5; the disease is cancer.